Have a feature idea you'd love to see implemented?
Let us know!
CLDX Celldex Therapeutics Inc
Price (delayed)
$25.14
Market cap
$1.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.58
Enterprise value
$1.63B
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which
Highlights
The company's gross profit has surged by 129% YoY and by 20% QoQ
Celldex Therapeutics's revenue has soared by 129% YoY and by 20% from the previous quarter
CLDX's quick ratio has surged by 179% year-on-year but it is down by 19% since the previous quarter
The debt has increased by 29% QoQ and by 8% YoY
Celldex Therapeutics's net income has decreased by 24% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of CLDX
Market
Valuations
Earnings
Shares outstanding
66.34M
Market cap
$1.67B
Enterprise value
$1.63B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
167.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
163.85
Revenue
$9.98M
Gross profit
$9.98M
Net income
-$154.08M
EBIT
-$154.08M
EBITDA
-$150.96M
Free cash flow
-$159.66M
Per share
Balance sheet
Liquidity
EPS
-$2.58
EPS diluted
-$2.58
Free cash flow per share
-$2.41
Book value per share
$11.86
Revenue per share
$0.15
TBVPS
$12.01
Total assets
$823.18M
Total liabilities
$37.27M
Debt
$3.09M
Equity
$785.91M
Working capital
$746.75M
Debt to equity
0
Current ratio
24.27
Quick ratio
23.58
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-1,513.2%
Gross margin
100%
Net margin
-1,544.5%
Operating margin
-1,871.3%
Return on assets
-20.5%
Return on equity
-21.5%
Return on invested capital
-24.1%
Return on capital employed
-19.5%
Return on sales
-1,544.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLDX stock price
How has the Celldex Therapeutics stock price performed over time
Intraday
-0.95%
1 week
-1.06%
1 month
-4.77%
1 year
-33.46%
YTD
-36.61%
QTD
-26.04%
Financial performance
How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$9.98M
Gross profit
$9.98M
Operating income
-$186.68M
Net income
-$154.08M
Gross margin
100%
Net margin
-1,544.5%
The company's gross profit has surged by 129% YoY and by 20% QoQ
Celldex Therapeutics's revenue has soared by 129% YoY and by 20% from the previous quarter
The net margin has increased by 46% YoY and by 15% QoQ
CLDX's operating margin is up by 39% year-on-year and by 12% since the previous quarter
Growth
What is Celldex Therapeutics's growth rate over time
Valuation
What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
2.12
P/S
167.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
163.85
CLDX's EPS is up by 6% from the previous quarter and by 2.6% YoY
The P/B is 44% lower than the 5-year quarterly average of 3.8 and 36% lower than the last 4 quarters average of 3.3
Celldex Therapeutics's equity has decreased by 3.4% from the previous quarter
Celldex Therapeutics's revenue has soared by 129% YoY and by 20% from the previous quarter
CLDX's price to sales (P/S) is 57% lower than its 5-year quarterly average of 390.2 and 45% lower than its last 4 quarters average of 301.6
Efficiency
How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has soared by 54% YoY and by 18% from the previous quarter
The ROE has soared by 50% YoY and by 17% from the previous quarter
The ROA is up by 48% YoY and by 16% QoQ
CLDX's ROS is up by 46% YoY and by 15% from the previous quarter
Dividends
What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLDX.
Financial health
How did Celldex Therapeutics financials performed over time
Celldex Therapeutics's total assets has soared by 194% YoY but it has decreased by 2.6% from the previous quarter
CLDX's quick ratio has surged by 179% year-on-year but it is down by 19% since the previous quarter
The debt is 100% lower than the equity
CLDX's debt to equity has dropped by 100% year-on-year
The debt has increased by 29% QoQ and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.